USA flag logo/image

An Official Website of the United States Government

Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / STTR
Agency Tracking Number:
R42CA141907
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
PA10-051
Small Business Information
MERCATOR MEDSYSTEMS, INC.
1670 Alvarado Street SAN LEANDRO, CA 94577-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma
Agency: HHS
Contract: 2R42CA141907-02
Award Amount: $1,148,429.00
 

Abstract:

DESCRIPTION (provided by applicant): Over 215,000 people will be diagnosed in 2008 with bronchial carcinoma in the U.S. according to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Currently, asthma afflicts22.9 million people in the U.S., and tracheomalacia is believed to afflict 3 million people in the U.S. In addition to these chronic or deadly conditions, intervention into the bronchial passageways with bronchoscopic procedures can cause bronchial granulation tissue that obstructs airflow. These diseases of the bronchi may potentially be treated with local, direct infusion of medications into the bronchial wall and adventitia (the tissue between smooth muscle layers and cartilage). In fact, data suggeststhat diseases of the bronchi arise in the sub-epithelial bronchial wall, and thus local treatment beyond the epithelium is warranted. Despite the magnitude of these problems and the potential for a simple solution, there has existed no device useful to deliver safely and reliably into the bronchial wall. Mercator MedSystems has developed a vascular adventitial infusion catheter that has FDA 510(k) clearance to market for use in humans, and now has modified the catheter to target injections into bronchial walls. This is an endoluminal balloon catheter which extrudes a single needle into the bronchial wall when the balloon is inflated, thus allowing direct therapeutic access to the bronchial adventitia. It has been discovered through Phase I research that broncho-adventitial delivery leads to cylindrical and longitudinal deposition of drugs around the bronchus, creating a natural drug-eluting reservoir. In this proposal, we hypothesize that by completing the development of the Mercator Micro-Infusion Catheter for bronchial use, we can show with statistical significance that local infusion of paclitaxel into the bronchial wall is safe for use in humans and effective at limiting airway occlusion in malignant disease. We intend to verify that the device can be usedin bronchi up to 16 mm diameter while remaining compatible with the 2.8 mm working channel of bronchoscopes (Specific Aim 1). After this, we will statistically prove that bronchial delivery of paclitaxel is safe in animals and leads to long-term retentionof chemotherapeutic doses (Specific Aim 2). Finally, we intend to show in a pilot human study that paclitaxel delivered to the airway wall can improve airway patency rates after malignant airway obstructions are removed (Specific Aim 3). We believe that the significance of this proposal lies in the facts that (a) we will test out a novel and innovative local drug delivery device for a recalcitrant clinical problem, (b) statistically showing a non-toxic dose of a common chemotherapeutic, anti-proliferativedrug like paclitaxel can have broad-ranging clinical impact, (c) bronchial adventitial therapy may be more effective in the prevention and treatment of bronchial maladies than inhalation or systemic therapies and (d) therapeutic success in the delivery ofpaclitaxel for the treatment of bronchial carcinoma could be rapidly translated to other clinical settings of bronchial narrowing. Indeed, all of the above suggest a huge commercial potential for the Mercator product, if these pilot studies are successful.PUBLIC HEALTH RELEVANCE: The relevance of this proposal lies in its potential to reduce morbidity and mortality associated with occlusive diseases of the bronchi, due to a lack of effective therapies for this important clinical problem.

Principal Investigator:

Kirk Seward
510-614-4555
kseward@mercatormed.com

Business Contact:

Kirk Seward
510-614-4555
kseward@mercatormed.com
Small Business Information at Submission:

MERCATOR MEDSYSTEMS, INC.
1670 Alvarado Street SAN LEANDRO, CA -

EIN/Tax ID: 194338503
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
STEWARD RESEARCHAND OTHER SPECIAL PROJECT CORPORATION
77 WARREN Street
BOSTON, MA 02135-
Contact: